Skip to Content
Merck
  • Mutual promotion of FGF21 and PPARγ attenuates hypoxia-induced pulmonary hypertension.

Mutual promotion of FGF21 and PPARγ attenuates hypoxia-induced pulmonary hypertension.

Experimental biology and medicine (Maywood, N.J.) (2019-02-05)
Gexiang Cai, Jingjing Liu, Meibin Wang, Lihuang Su, Mengsi Cai, Kate Huang, Xiuchun Li, Manxiang Li, Liangxing Wang, Xiaoying Huang
ABSTRACT

In this study, we reported for the first time that FGF21 alleviated hypoxia-induced pulmonary hypertension through attenuation of increased pulmonary arterial pressure, pulmonary arterial remodeling and collagen deposition in vivo, and we confirmed the mutual promotion of FGF21 and PPARγ in hypoxia-induced pulmonary hypertension. Additionally, we found that FGF21 and PPARγ mutually promote each other's expression via the AMPK/PGC-1α pathway and KLB protein in vitro and in vivo. Pulmonary hypertension is a progressive and serious pathological phenomenon with a poor prognosis, and current therapies are highly limited. Our results provide novel insight into potential clinical therapies for pulmonary hypertension and establish the possibility of using this drug combination and potential dosage reductions in clinical settings.